Therapeutics News and Research

RSS

$IOF report predicts major increase in osteoporosis fractures in the Middle East and Africa$

IOF report predicts major increase in osteoporosis fractures in the Middle East and Africa

A new audit report issued today by the International Osteoporosis Foundation (IOF) shows that osteoporosis is a serious and growing problem throughout the Middle East and parts of Africa.

22 Oct 2011

Small molecule selectively blocks gene activity regulated by thyroid hormone

A small molecule developed at St. Jude Children's Research Hospital advances progress toward more tailored drugs in research that also offers insight into the biology of thyroid hormone.

22 Oct 2011

Janssen announces FDA label update approval for PREZISTA HIV tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA (darunavir) tablets to include 192-week data from the ARTEMIS study.

22 Oct 2011

Xencor commences XmAb5871 Phase 1 trial in autoimmune diseases

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today the initiation of a Phase 1 clinical trial of XmAb5871, the company's therapeutic antibody for the treatment of autoimmune diseases.

22 Oct 2011

Allos terminates AMAG merger agreement with AMAG

Allos Therapeutics, Inc. announced today that the Agreement and Plan of Merger and Reorganization entered into by and among Allos, AMAG and Alamo Acquisition Sub, Inc. on July 19, 2011, as amended on August 8, 2011, has been terminated.

22 Oct 2011

RSV medication from specialty pharmacies increases likelihood of children receiving recommended doses

Children given an injectable medication to help prevent severe respiratory illness had a 17.6 percent higher likelihood of receiving the American Academy of Pediatrics (AAP) recommended doses when they were administered through a specialty pharmacy rather than a traditional pharmacy, according to a new study released today by pharmacy benefit manager Prime Therapeutics (Prime).

21 Oct 2011

Pradaxa for stroke treatment results in higher costs

Treating patients with the new blood thinning medication dabigatran (Pradaxa), instead of warfarin results in significantly higher per patient costs and higher net costs per stroke avoided, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime).The study will be presented today at the Academy of Managed Care Pharmacy's Educational Conference in Atlanta, Ga.

21 Oct 2011

UH scientists recommend new drug strategies for chronic diseases

Researchers at the University of Houston (UH) are recommending a new strategy for developing drugs to treat cancer, multiple sclerosis, Alzheimer's and cardiovascular diseases.

21 Oct 2011

Future-Directed Therapy for patients with major depression

Patients with major depression do better by learning to create a more positive outlook about the future, rather than by focusing on negative thoughts about their past experiences, researchers at Cedars-Sinai say after developing a new treatment that helps patients do this.

20 Oct 2011

Breakthrough in development of effective therapy against Hendra virus

A team of Federal and university scientists reports a breakthrough in the development of an effective therapy against a deadly virus, Hendra virus. The results of their study, "A Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus Challenge," will appear in Science Translational Medicine online.

20 Oct 2011

Comprehensive roadmap promises to improve cancer immunotherapy development

The Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI) and the Association for Cancer Immunotherapy (CIMT) have issued a joint white paper, published in the October 13 issue of Nature Biotechnology, outlining a comprehensive roadmap that promises to help improve and facilitate the path forward in the development of novel immunotherapies for cancer.

19 Oct 2011

AAGL to showcase innovative surgical approaches, teaching tools at 40th Global Congress

Technology has radically changed the way surgeons practice medicine, and nowhere is this more evident than in the field of gynecologic endoscopy. AAGL, the oldest professional organization devoted to teaching minimally invasive treatment for women's health problems, will showcase a number of innovative surgical approaches and teaching tools among the hundreds of postgraduate courses and practice labs offered at its annual Global Congress, November 6-11, 2011 at the Westin Diplomat in Hollywood, FL.

19 Oct 2011

RetroSense, WSU sign license agreement for channelrhodopsin-based approaches

RetroSense Therapeutics, LLC, a Michigan-based company, announced that it has executed its exclusive, worldwide option and signed a license agreement for novel gene-therapy approaches for treating blindness developed at Wayne State University's School of Medicine.

19 Oct 2011

JPO issues new patent for Genprex's lead lung cancer candidate

A new patent covering tumor suppression technologies, including the company's lead product candidate Oncoprex, was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors.

19 Oct 2011

Commercialization strategies for next-generation medicines

The Center for Biotechnology at Stony Brook University, in collaboration with Demy-Colton Life Science Advisors, and key opinion leaders from the biotech and biopharmaceutical industries, academia, medical research foundations, and investment community, has organized a two-day event to forge partnerships to accelerate the development of new treatments for some of the world's most devastating diseases affecting millions.

18 Oct 2011

HMS launches Initiative in Systems Pharmacology

Taking aim at the alarming slowdown in the development of new and lifesaving drugs, Harvard Medical School is launching an Initiative in Systems Pharmacology, a comprehensive strategy to transform drug discovery by convening biologists, chemists, pharmacologists, physicists, computer scientists and clinicians to explore together how drugs work in complex systems.

18 Oct 2011

TPP, University of Dundee sign collaboration agreement for drug development fund

TPP Global Development Ltd announced a collaboration agreement with the University of Dundee to establish a drug development fund.

18 Oct 2011

Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.

18 Oct 2011

New treatment approach for septic Listeria infection

Research underway at the Trudeau Institute could lead to new treatments for people sickened by Listeria and other sepsis-causing bacteria. Dr. Stephen Smiley's laboratory has published a study in the scientific journal Infection and Immunity that supports a new approach to treating these infections.

18 Oct 2011

Brain tumour discovery offers drug treatment hope

Australian scientists have played a key role in the identification of a new biochemical mechanism that allows brain tumours to survive and grow, offering hope of new drug treatments for some of the most aggressive tumours.

17 Oct 2011